Biologics Spine Kuros Biosciences USA, Inc. Announces an Exclusive Strategic Agreement with the Medtronic Spinal Division byJosh SandbergJanuary 7, 2025
Biologics Extremities Top Stories Kuros Biosciences Expands into Extremities Markets byTim AllenNovember 19, 2024
Biologics Extremities Top Stories Foot Innovate Welcomes New Corporate Partner: Kuros Biosciences byTim AllenOctober 9, 2024
Financial Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023 byJosh SandbergMarch 13, 2024
Biologics Regulatory Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand byJosh SandbergJanuary 31, 2024
Biologics Spine Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA byJosh SandbergDecember 27, 2023
Biologics Regulatory Spine Kuros Biosciences’s MagnetOs Granules Cleared by FDA for Expanded Spinal Indications byChris StewartFebruary 3, 2022
Biologics Spine Kuros Biosciences Reports Continued Increase in MagnetOs U.S. Sales byJosh SandbergOctober 26, 2021
Biologics Financial Kuros Biosciences Announces MagnetOs Sales and Distribution Agreements Across Northern Europe byChris StewartMarch 2, 2021
Biologics Spine Kuros Biosciences Announces Treatment of the First Patient in its Spinal Fusion Trial with Fibrin-PTH byJosh SandbergSeptember 1, 2020
